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tIs Acute Hemodynamic
Response a Predictor of
Long-Term Outcome in
Cardiac Resynchronization Therapy?
In a recent issue of the Journal, Duckett et al. (1) published a study
indicating that the acute hemodynamic response ([AHR], assessed
by LVdP/dtmax, the maximum rate of rise of left ventricular
pressure) predicts reverse remodeling ([RR], which is the decrease
in left ventricular end-systolic volume) in recipients of cardiac
resynchronization therapy (CRT). At first glance, these results
seem long-awaited and fit with physiological ideas about the action
of CRT. In an editorial comment, Bozkurt and Ramasubbu (2)
mention that “whether a nonresponse to early surrogate testing will
identify the chronic nonresponder to CRT, with respect to hard
clinical endpoints, remains to be answered.” Recently, we investi-
gated the relation between LVdP/dtmax and survival in the
majority of CRT patients treated in 2 centers over a 5-year period
(n  285) (3). Absolute LVdP/dtmax at baseline predicted 1-year
mortality (hazard ratio: 0.79), but the change in LVdP/dtmax upon
RT had no relation to outcome. As frequent users of LVdP/
tmax for CRT optimization, we were initially surprised and
disappointed by these findings. However, the data are strong and
consistent with a recent Japanese study (4). Therefore, we think
that there is stronger evidence against than in favor of a relation
between AHR and long-term outcome. The apparently contradic-
tory findings by Duckett et al. (1) may be (in part) explained by
several limitations of their study: 1) its sample size was small (n 
32), explaining why adjusting the cutoff value for percentage of
change in LVdP/dtmax from 10% to 11.1% (a small difference,
onsidering the 8% baseline drift in LVdP/dtmax), increased
specificity from 64% to 86%; 2) switching from natural sinus
rhythm to atrial pacing caused an unusually large (11%) increase
in LVdP/dtmax; 3) it is not mentioned whether these patients were
a selected subgroup or consecutive patients; 4) the relation between
AHR and RR was only evaluated by dichotomously separating
responders and nonresponders, without showing a scatter plot or
linear regression; and 5) it was not reported whether absolute
baseline LVdP/dtmax related to RR. Because baseline LVdP/dtmax
strongly determines percentage of change in LVdP/dtmax, it may
seem that the percentage of change in LVdP/dtmax relates to RR,
although it is actually the absolute baseline value. Summarizing, we
think that there are some questions regarding the reported relation
between AHR and RR (1) and that there is even less evidence to
support using AHR to predict long-term outcome in CRT.
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Reply
We thank Dr. Prinzen and colleagues for their interest in our study
(1). They comment that our results fit with physiological concepts
regarding cardiac resynchronization therapy but are not supported
by their findings that baseline rather than change in (the maximum
rate of LV pressure rise LVdP/dtmax) predicted survival (2).
We acknowledge that our study was limited by a small sample
ize and that our patients were a selected group meeting criteria for
n inclusive research protocol. We used a 10% rise in LVdP/dtmax
to define acute response, which was supported by the receiver-
operator analysis giving a cutoff of 11.1%, although this small
increase did change the specificity to 86% from 64%. We found a
moderate correlation between percentage rise in LVdP/dtmax and
extent of remodeling (r  0.6) but no relationship between
baseline LVdP/dtmax and remodeling. We used baseline atrial
acing to account for heart rate changes causing a rise in dP/dtmax
as described previously and our baseline dP/dtmax was comparable
o the reported study (2).
We note the findings of Bogaard et al. (2) and would like to
ighlight several important differences between studies. Their
atient population was different and predominantly ischemic: 56%
ersus 36% in our study. It is well described that cardiac resyn-
hronization therapy response is worse in ischemic cardiomyopa-
hy and 70% of their patients with events had ischemic cardiomy-
pathy (2). Importantly, we used LVdp/dtmax to guide left
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March 27, 2012:1198–9ventricular lead placement, whereas Bogaard et al. measured
dp/dtmax after implantation and a guided approach may explain
ifferences in remodeling and outcome. In keeping with our
esults, optimal left ventricular lead positioning produces marked
ariation in acute dp/dtmax (3), better remodeling, and reduced
events (heart failure hospitalizations/death) (4). It is also important
to appreciate that remodeling may not always correlate with
clinical outcome especially in ischemic cardiomyopathy patients.
Bogaard et al. (2) reported clinical outcome and remodeling or
hospitalization for heart failure. Data were not consistently avail-
able or reported (nearly 50% of deaths were noncardiac or
unknown) and they state that whether acute improvement in
dP/dtmax correlates to morbidity still needs to be determined (2).
In summary, we are in agreement with Prinzen et al. that a
prospective randomized controlled study will be needed to confirm
a favorable effect of LVdP/dtmax-guided therapy on prognosis and
functional status after cardiac resynchronization therapy.
*Simon G. Duckett
Matthew R. Ginks, MD
Anoop K. Shetty
Julian Bostock, MSc
Jaswinder S. Gill, MD
Shoaib Hamid, MD
Stam Kapetanakis, MD
Eliane Cunliffe, BSc
Reza Razavi, MD
Gerry Carr-White, PhD
C. Aldo Rinaldi, MD
*Division of Imaging Sciences
The Rayne Institute
St Thomas’ Hospital
London SE1 7EH
United Kingdom
E-mail: simon.duckett@kcl.ac.uk
doi:10.1016/j.jacc.2011.10.902
EFERENCES
1. Duckett SG, Ginks M, Shetty AK, et al. Invasive acute hemodynamic
response to guide left ventricular lead implantation predicts chronic
remodeling in patients undergoing cardiac resynchronization therapy.
J Am Coll Cardiol 2011;58:1128–36.
2. Bogaard MD, Houthuizen P, Bracke FA, et al. Baseline left ventricular
dP/dtmax rather than the acute improvement in dP/dtmax predicts
clinical outcome in patients with cardiac resynchronization therapy. Eur
J Heart Fail 2011;13:1126–32.
3. Derval N, Steendijk P, Gula LJ, et al. Optimizing hemodynamics in
heart failure patients by systematic screening of left ventricular pacing
sites: the lateral left ventricular wall and the coronary sinus are rarely the
best sites. J Am Coll Cardiol 2010;55:566–75.4. Ypenburg C, van Bommel RJ, Delgado V, et al. Optimal left ventricular
lead position predicts reverse remodeling and survival after cardiac
resynchronization therapy. J Am Coll Cardiol 2008;52:1402–9.
ACCF and AHA
Presidents’ Letter on MEDCAC
On January 25, 2012, the Centers for Medicare and Medicaid
Services (CMS) convened a meeting of the Medicare Evidence
Development and Coverage Advisory Committee (MEDCAC) to
review the evidence on the management of patients with carotid
atherosclerosis with particular reference to revascularization. We are
gratified that MEDCAC’s recommendations reflect those in the
ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/
SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Pa-
tients With Extracranial Carotid and Vertebral Artery Disease (1).
The MEDCAC decision reaffirms the utility and validity of the
mutlidisciplinary guideline that has been endorsed by these orga-
nizations as a sound basis for clinical practice.
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